- Home
- AMRN
as 04-18-2025 1:31pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 189.2M | IPO Year: | 1993 |
| Target Price: | $7.00 | AVG Volume (30 days): | 103.6K |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.00 - $20.60 | Next Earning Date: | 04-30-2025 |
| Revenue: | $228,614,000 | Revenue Growth: | -25.51% |
| Revenue Growth (this year): | -16.73% | Revenue Growth (next year): | 5.18% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
GlobeNewswire
12 days ago
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
GlobeNewswire
19 days ago
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
a month ago
Amarin Shareholders Calls for Strategic Review
![New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo](https://cdn.finquota.com/news/ea5eded0-8dd7-4eb4-895d-3c70a26d3bf0.jpg)
GlobeNewswire
a month ago
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Zacks
a month ago
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
GuruFocus.com
a month ago
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ...
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.